The global market for Infectious Disease Therapeutics was estimated at US$147.1 Billion in 2024 and is projected to reach US$222.4 Billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Infectious Disease Therapeutics market.
Global Infectious Disease Therapeutics Market - Key Trends and Drivers Summarized
Why Is the Infectious Disease Therapeutics Market Crucial for Global Health?
Infectious disease therapeutics are a critical segment of the healthcare industry, focusing on the treatment and prevention of diseases caused by pathogens such as bacteria, viruses, fungi, and parasites. These therapeutics include antibiotics, antivirals, antifungals, and vaccines, which are vital in combating illnesses ranging from influenza and HIV to emerging infectious diseases like COVID-19. As infectious diseases remain a significant cause of morbidity and mortality worldwide, particularly in developing regions, the demand for effective therapeutics is substantial. Infectious disease therapeutics are also essential in managing antimicrobial resistance (AMR), which poses a growing global health threat as common pathogens become resistant to existing treatments.How Are Technological Advancements Shaping the Infectious Disease Therapeutics Market?
The infectious disease therapeutics market is undergoing rapid advancements due to breakthroughs in drug development, genomics, and biotechnology. The rise of precision medicine and genomic sequencing is enabling more targeted therapies that are specific to the genetic makeup of pathogens, improving treatment efficacy. Furthermore, the development of novel drug delivery systems, such as nanoparticle-based therapies, is enhancing the bioavailability and effectiveness of therapeutics. Innovations in vaccine technology, particularly mRNA vaccines, have transformed the way vaccines are developed and deployed, offering faster and more flexible responses to emerging diseases. These technological advancements are driving the development of next-generation therapeutics that are more effective, safer, and capable of addressing drug-resistant infections.How Do Market Segments Define the Growth of the Infectious Disease Therapeutics Market?
Drug types include antibiotics, antivirals, antifungals, and vaccines, with vaccines leading the market due to their preventive role in managing infectious diseases. Disease types include bacterial, viral, fungal, and parasitic infections, with viral infections such as HIV, influenza, and COVID-19 representing the largest segment as they pose significant global health challenges. Distribution channels include hospitals, retail pharmacies, and online pharmacies, with hospitals being the dominant channel due to the critical nature of treating infectious diseases in clinical settings. The market is expanding rapidly in regions such as Asia-Pacific and Africa, where infectious diseases are highly prevalent and access to therapeutics is improving.What Factors Are Driving the Growth in the Infectious Disease Therapeutics Market?
The growth in the infectious disease therapeutics market is driven by several factors, including the rising prevalence of infectious diseases, advancements in drug and vaccine development, and increasing global healthcare expenditure. Emerging infectious diseases and outbreaks, such as COVID-19, have highlighted the urgent need for effective therapeutics, driving investment in research and development. Additionally, the growing threat of antimicrobial resistance (AMR) is fueling the demand for new antibiotics and alternative therapies. Technological advancements in biotechnology and genomics are also accelerating the development of targeted and personalized therapies, improving treatment outcomes. Furthermore, increased healthcare spending, particularly in developing regions, is expanding access to life-saving treatments and vaccines, further supporting market growth.SCOPE OF STUDY:
The report analyzes the Infectious Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Disease (HIV, Malaria, TB, Other Diseases); Target Organism (Antibacterial, Antiviral, Antifungal, Antiparasitic, Other Target Organisms); End-Use (Hospitals, Clinics, Other End-Uses)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the HIV segment, which is expected to reach US$113.7 Billion by 2030 with a CAGR of a 8.1%. The Malaria segment is also set to grow at 6.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $38.1 Billion in 2024, and China, forecasted to grow at an impressive 10.8% CAGR to reach $54.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Infectious Disease Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Infectious Disease Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Infectious Disease Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as BioCryst Pharmaceuticals Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Gilead, GlaxoSmithKline plc and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 43 companies featured in this Infectious Disease Therapeutics market report include:
- BioCryst Pharmaceuticals Inc.
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Gilead
- GlaxoSmithKline plc
- Janssen Pharmaceutical Inc.
- Merck and Co. Inc.
- Novartis AG
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioCryst Pharmaceuticals Inc.
- Boehringer Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Gilead
- GlaxoSmithKline plc
- Janssen Pharmaceutical Inc.
- Merck and Co. Inc.
- Novartis AG
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 94 |
Published | June 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 147.1 Billion |
Forecasted Market Value ( USD | $ 222.4 Billion |
Compound Annual Growth Rate | 7.1% |
Regions Covered | Global |